

CURRICULAM VITAE

INOEL RIVERA, M.D.



Winter Park Urology Associates, P.A.
Urological Ambulatory Surgery Center, Inc.

**1812 North Mills Avenue
Orlando, FL 32803**

PERSONAL DATA

Date of Birth: May 21, 1965
Place of Birth: Mayaguez, Puerto Rico
Citizenship: U.S.
Marital Status: Married to Carmen Rivera

WORK HISTORY:

12/00 to Present Winter Park Urology Associates
Orlando, FL

APPOINTMENTS:

07/03 to present Florida State University
School of Medicine-Department of Clinical Science
Clinical Assistant Professor

2001 to present University of Florida
Division of Urology
Assistant Clinical Professor of Surgery

03/98 to 11/00 University of Florida
Shands Hospital
Department of Surgery
Division of Urology
Assistant Professor

11/97 to 03/98 University of Florida
Shands Hospital
Department of Surgery
Division of Urology
Clinical Assistant Professor

06/97 to 10/97 University of Florida
Shands Hospital
Department of Surgery
Division of Urology
Acting Chief of Urologic Oncology

07/96 to 06/97 University of Florida
Shands Hospital
Department of Surgery
Division of Urology
Adjunct Assistant Professor

07/96 to 09/99 Veterans Administration Hospital
Gainesville, FL
Department of Surgery
Attending Urologist

INOEL RIVERA, M.D.

EDUCATION AND HONORS

- 07/95 to 06/96** University of Florida
Shands Hospital
Department of Surgery
Division of Urologic Oncology
Zev Wajsman, M.D.
Urologic Oncology Fellowship
University of Florida – Pfizer Award for Excellence in Teaching
- 07/92 to 06/95** University of Puerto Rico School of Medicine
Rio Piedras, Puerto Rico
Department of Surgery
Urology Section
- 07/90 to 06/92** University of Puerto Rico, School of Medicine
Rio Piedras, Puerto Rico
(Accredited by the Liaison Committee of Medical Education)
Department of Surgery
Completed Straight Surgery Internship
PGY-1, June 1991
Completed Straight Surgery, PGY-2, June 1992
- 07/86 to 06/90** University of Puerto Rico, School of Medicine
Rio Piedras, Puerto Rico
(Accredited by the Liaison Committee of
Medical Education)
M.D. - June 1990
- 1983-1986** University of Puerto Rico, Mayaguez Campus
Mayaguez, Puerto Rico
B.S. in Natural Sciences – 1987
Magna Cum Laude
UPR Dean’s Honor List – 1983-84-85
- 1996-1998** Certified Space Shuttle Medical Support Team
- June 1996** Pfizer Scholars in Urology Award

LICENSURES

- | | |
|---|----------------------------|
| NBME Part I | Approved in September 1989 |
| NBME Part II | Approved in April 1990 |
| NBME Part III | Approved in March 1991 |
| Puerto Rico Board of
Medical Examination | Approved in April 1989 |
| The American Board
of Urology Part I | Approved on June 1, 1995 |
| Part II | Approved in February 1998 |
| State of Florida Medical
License #69538 | Approved in October 1995 |
| Puerto Rico Medical License | Approved August 1995 |
| Fellow of American college
of Surgeons | Effective October 2000 |
| DEA – BR4756081 | |

INOEL RIVERA, M.D.

RESEARCH EXPERIENCE

- 2004-Present** Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Study of Study Drug for the Prevention of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy.
- 2004-Present** Sub-Investigator: Study of XXXX in Women of Different Demographic Characteristics and Co-morbidities With Stress Urinary Incontinence: Evaluation of Efficacy and Safety.
- 2004-Present** REALISE: Real Life Safety and Efficacy of Levitra®
- 2003-Present** Sub-Investigator: A Double-Blind, Placebo-Controlled Study of Frequency and Urgency Using Study Drug 0.5mg Twice Daily For 12 Weeks Followed by a 6-Month Open Label Treatment Phase in Patients with Overactive Bladder.
- 2003-Present** Sub-Investigator: A Multicenter, Open Label, Flexible Dose Study to Investigate the Use Patterns of Viagra® (sildenafil citrate) And The Ability of Investigators To Further Optimize Subject Satisfaction With Viagra® Through Customized Instruction.
- 2003-2004** Sub-Investigator: An Open-Label Study to Evaluate the Efficacy and Safety of Study Drug Administered 'On Demand' to Men of Various Populations with Erectile Dysfunction.
- 2003-Present** Sub-Investigator: A Phase 3, Parallel Group, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Study Drug Sustained Release in Subjects with Overactive Bladder Syndrome.
- 2003-2003** Sub-Investigator: A Double-Blind, Placebo-Controlled Randomized US/Latin America Study to Evaluate the Effect of Study Drug Prolonged Release on Nocturia In Patients with Symptoms of Overactive Bladder (OAB)
- 2003-Present** Sub-Investigator: A Double-Blind, Placebo-Controlled Parallel Group Study of the Efficacy and Safety of Study Drug 0.5mg Administered Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer.
- 2002-Present** Sub-Investigator: A Phase 3B, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Study Drug in Subjects with Overactive Bladder.
- 2002-2003** Principal Investigator: An Open-label Trial on the Effect of IV Study Drug 4mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients with Bone Metastasis.
- 2002-2002** Principal Investigator: A Randomized, Placebo-Controlled, Serum-Level Targeted Study Investigating the Safety and Pharmacokinetics of Orally Administered Study Drug in Patients with Various Malignancies.
- 2002-2002** Principal Investigator: A Randomized, Double-Blind, Parallel Group, Multi-center, Study to Investigate the Time to Onset of Action of 20mg Study Drug Compared to Placebo in Males with Erectile Dysfunction.
- 2001-Present** Sub-Investigator: A Multicenter, Phase IIB, Four Arm, Dose Finding, Randomized, Placebo-Controlled Study to Determine the Long Term Prostate Cancer Chemoprevention Efficacy and Safety of 20mg, 40mg & 60mg Daily of Study Drug in Men with High Grade Prostate Intraepithelial Neoplasia (PIN).

2001-2002 Sub-Investigator: A Phase III, Double-Blind, Randomized, Parallel Study Evaluating the Safety and Efficacy of Study Drug in the Treatment of Male Erectile Dysfunction.

2001-2002 Sub-Investigator: Double-Blind, Placebo-Controlled Study of Sustained Release Study Drug in Subjects with Symptoms of Overactive Bladder of Urgency, Frequency and Urinary Incontinence.

2001-2002 Sub-Investigator: An Investigation Of The NMP22 Point of Care (POC) Device As An Aid In The Monitoring of Bladder Cancer Patients.

2001-2002 Sub-Investigator: An Investigation Of The NMP22 Point of Care (POC) Device As An Aid In The Screening of Patients At Risk For Bladder Cancer.

1999-2000 Principal Investigator: Extended Safety and Efficacy Study of Duros™ Leuprolide Implant in Patients with Prostate Cancer.

1997-2000 Principal Investigator: Safety and Efficacy Study of Duros™ Leuprolide Implantable Therapeutic System in Patients with Prostate Cancer.

1997-2000 Principal Investigator-Feasibility, Functionality and Dose Ranging Study of Duros™ Leuprolide Implantable Therapeutic System in Patients with Advanced Prostate Cancer.

1997-2000 Co-Principal Investigator-Combined Intravesical Immunotherapy using BCG and Recombinant Interferon for Treatment of Recurrent Superficial Transitional Cell Carcinoma of the Bladder. Principal Investigator-Zev Wajsman, M.D.

1997-2000 Co-Principal Investigator-Phase III Randomized Study of a Single Adjuvant Instillation of Intravesical AD 32 versus No Adjuvant Therapy Immediately Following Transurethral Resection in Patients with Multiple Superficial Bladder tumors Principal Investigator – Zev Wajsman, M.D.

1995-2000 Co-Principal Investigator-Phase II Intravesical AD 32 in Patients with Transitional Cell Carcinoma. Principal Investigator – Zev Wajsman, M.D.

1995-2000 Co-Principal Investigator-Phase II Intravesical AD 32 in Patients with Carcinoma In Situ of the Bladder Who have Failed or Have Recurrence Following Treatment with BCG. Principal Investigator – Zev Wajsman, M.D.

1995-2000 Co-Principal Investigator-Randomized Prospective Study Comparing Radical Prostatectomy Alone versus Radical Prostatectomy Preceded by Androgen Blockade with Clinical DB2 Prostate Cancer. Principal Investigator – Zev Wajsman, M.D.

1995-2000 Co-Principal Investigator-RTOG 95:06: Phase I/II Trial of Transurethral Surgery Plus Induction of Chemoradiotherapy Followed Either By Selective Bladder Preservation of Radical Cystectomy as Determined by Initial Response and Operability in Patients with Muscle-invading Bladder Cancer. Principal Investigator – Zev Wajsman, M.D.

1995-2000 Co-Principal Investigator-A Randomized, Comparative Trial of Casodex versus Flutamide Used In Combination with Medical Castration in Patients With Untreated Metastatic Prostate Cancer. Principal Investigator – Zev Wajsman, M.D.

1984-1985 Microsurgery in the Musca domestica eye: Research in mechanism of action of the pseudopupil in the Musca domestica.
Proctor: Michael Wilcox, Ph.D. in Biophysics – 1984-1985.

INOEL RIVERA, M.D.

PRESENTATIONS

1999

Treatment of Invasive Bladder Cancer there is a place for radical surgery in the year 2000? Florida Urological Society.

1999

New Advances in Radical Bladder Surgery movie submitted for American Urological Association in the year 2000.

1997

Radioactive Seed Implantation for the Treatment of Prostate Cancer. Puerto Rico Urological Society.

1998

Radioactive Seed Implantation for the Treatment of Prostate Cancer. Selected topics in Urology.

1998

Treatment for Localized Prostate Cancer. Radiation Oncology Clinical Research Seminar.

April 1997

The Impact Of Interinstitution Pathologic Review on the Management of Patients With Urologic Malignancies, American Urological Association Meeting.

September 1996

Acute Normovolemic Hemodilution: A Cost Efficient Alternative to Autologous Blood in Urologic Surgery. Guest speaker at the Puerto Rico Urological Association Annual Meeting.

March 1995

Treatment of Metastatic Squamous Cell Carcinoma of the Penis to the Inguinal Lymph Nodes at the Southeastern Section of the American Urologic Association.

February 1994

Tensor Fascia Lata Myocutaneous Flap in Inguinal Lymphadenectomy For Metastatic Carcinoma of Penis Presented at the Second Annual Florida Resident Meeting – February 1994.

ABSTRACTS:

2000

Bladder Sparing Treatment of Invasive Bladder Cancer. **Inoel Rivera, MD** and Zev Wajsman Accepted: Journal of Moffitt Cancer Center

2000 Pending

The Outcome of Patients with Carcinoma of the Prostate treated with Adjuvant and Salvage Radiation after Radical Prostatectomy. Endre Neulander, **Inoel Rivera-Ramirez**, Robert Zlotecki and Zev Wajsman. Pending

2000 Pending

The effect of the follow-up Cytoscopy interval on the Outcome of patients with Bladder tumors receiving Adjuvant Intravesical Instillation. Endre Neulander, **Inoel Rivera-Ramirez**, Lorenzo Luciani, Nadeem Dahani and Zev Wajsman. Pending.

March 2000

The Outcome after Radical Prostatectomy in Patients with Preoperative PSA above 15 ng/ml. Endre Neulander, **Inoel Rivera-Ramirez**, Gerard Curtis, Nadeem Dahani and Zev Wajsman. Submitted to the SE Section of the AUA, March 2000

November 1999

The Simple Cystectomy in High Risk Patients Requiring Urinary Diversion. Endre Z. Neulander, **Inoel Rivera-Ramirez** and Zev Wajsman. Accepted at the International Bladder Symposium, Washington, D.C., November 4-7.

March 1999

Combined Intravesical Immunotherapy using BCG and Recombinant Interferon for Treatment of Refractory Carcinoma In Situ (CIS). Curtis G., Wright N., **Inoel Rivera-Ramirez** and Zev Wajsman.

June 1998

A Phase I/II Dose Ranging Study of Duros (Leuprolide) Implantable Therapeutic System in Patients with Advanced Prostate Cancer. Jackson, R., Flower, Jackson, MS,; James E. Gottesman, Seattle, WA; Stephan F. Bardot, New Orleans, LA; C. Frederick Reid, Winston-Salem, NC; Gerald L. Andriole, St. Louis, MO; Peter H. Bernhard, Minneapolis, MN; **Inoel Rivera-Ramirez, Gainesville, FL**; John A. Libertino, Burlington, MA; and Mark S. Soloway, Miami, FL.

- April 1997** The Impact of Interinstitution Pathologic Review of Management of Patients With Urologic Malignancies.
- March 1997** The Bladder Tumor Antigen Test vs. Voided Urine Cytology for Detecting Recurrent Bladder Cancer.
- March 1997** Acute Normovolemic Hemodilution: A Cost Efficient Alternative to Autologous Blood in Urologic Surgery.
- March 1995** Treatment of Metastatic Squamous Cell Carcinoma of The Penis to the Inguinal Lymph Nodes at the Southeastern Section of the American Urologic Association

PUBLICATIONS

- Inoel Rivera-Ramirez**, Zev Wajsman: Bladder-Sparing Treatment of Invasive Bladder Cancer. *CANCER CONTROL*, Journal of the Moffitt Cancer Center; Vol. 7, 340-346, 2000.
- Endre Z. Neulander, **Inoel Rivera-Ramirez**, et al: Radical Prostatectomy in Patients with High Preoperative PSA. *UROLOGY (in press)* 2000.
- January 1998** Cristoforo L. Cama, **Inoel Rivera-Ramirez**, Zev Wajsman; Male Genitalia's Malignancy, Jacksonville Medicine. CME credits
- 2001** **Inoel Rivera**, Zev Wajsman: Cancer of the Kidney and Ureter. *Surgical Oncology: Contemporary Principles & Practice*. 17A pp. 753-767.
- December 1997** William M. Murphy, **Inoel Rivera-Ramirez**, Camilo A. Medina, Nancy J. Wright and Zev Wajsman: The Bladder Tumor Antigen (BTA) Test Compared to Voided Urine Cytology in the Detection of Bladder Neoplasms. *The Journal of Urology*; Vol. 158, 2102-2106.

SOCIETIES AND COMMITTEES

Florida Medical Association – 2000
 Puerto Rico Urological Association – 1998
 American Urological Association – 1997
 Member of the Committee for the Revision of the MCAT, 1988
 Beta-Beta-Beta Honor Society, 1984-1986
 Florida Urological Society – 1998
 O.R. Committee with Shands Hospital at the University of Florida
 Collaborator – State of Florida Prostate Cancer Task Force-1999
 Peer reviewer for the Journal of Urology

Updated 3/2004